摘要
目的:建立测定添加在降糖中成药中的格列吡嗪、格列本脲、格列齐特、格列喹酮、格列美脲、盐酸吡格列酮、盐酸罗格列酮、那格列奈、瑞格列奈共9种化学降糖药的高效液相分析方法。方法:色谱柱:Thermo C_(18)(150 mm×4.6 mm,5μm),流动相:醋酸盐缓冲溶液(10 mmol·L^(-1)醋酸铵和20 mmol·L^(-1)三乙胺,醋酸调pH至5.5)-乙腈(61:39),流速:1 ml·min^(-1),检测波长:210 nm,柱温:30℃,进样20μl。结果:9种化学降糖药完全分离,检出限为4～18 ng;9种药物具有宽的线性范围和良好的线性关系(r≥0.999 4);日内、日间RSD分别为0.09%～1.42%和0.30%～1.88%;在中药中的加样回收率除个别药物低浓度外均大于80%,RSD为0.26%～5.91%。结论:该方法用于检测中成药中的化学降糖药快速、简便、高效。
Objective： To establish the HPLC method for the simultaneous determination of nine anti-diabetic agents in chinese traditional patent medicines. The chemical anti-diabetic agents were glipizide, glibenclamide, gliclazide, gliquizone, glimepiride, piolita- zone hydrochloride, rosiglitazone hydrochloride, nateglinide, repaglinide. Method： The Thermo Cls analytical column （ 150 mm x 4.6 mm,5txm） was used,the mobile phase was acetonitrile-acetate buffer（ 10 mmol-L-1 ammonium acetate and 20 mmol. L-ltriethyl- amine, the pH of solution was adjusted to 5.5 using acetic acid） （61： 39）, the temperature was 30 ~C. Result： The lowest detectable limits were 4-18 ng, the linear relation and range of each component was obtained, and correlation coetticients were better within their ranges （r~〉0. 999 4）. Intra-day and inter-day relative standard deviations（RDSs） were 0. 09%-1.42% and 0. 30%-1.88% respec- tively. The average recoveries in different kinds of chinese traditional patent medicine were more than 80% except for the low concentra- tion of glimepiride was 46.5% ,RSDs of recoveries were 0. 26% -5.91%. Conclusion： The study reveals the method can be used in analysis of anti-diabetic drugs in chinese traditional patent medicine, and it is rapid, convenient, economic specific and accurate.
出处
《中国药师》
CAS
2010年第4期465-467,共3页
China Pharmacist
基金
北京科委基金(编号:D0206016040131)
北京东城区科委基金(编号:200622)
关键词
格列吡嗪
格列本脲
格列齐特
格列喹酮
格列美脲
盐酸吡格列酮
盐酸罗格列酮
那格列奈
瑞格列奈
高效
液相色谱
降糖中成药
Glipizide
Glibenclamide
Gliclazide
Gliquizone
Glimepiride
Piolitazone hydrochloride
Rosiglitazone hydrochlo- ride
Nateglinide
Repaglinide
HPLC
Anti-diabetic chinese traditional patent medicine
